Summary
Global Markets Direct’s, ‘Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2016’, provides an overview of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)
- The report reviews pipeline therapeutics for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) therapeutics and enlists all their major and minor projects
- The report assesses Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Alvogen Korea Co., Ltd.
AnGes MG, Inc.
AstraZeneca Plc
Athersys, Inc.
Bayer AG
Betagenon AB
CardioVascular BioTherapeutics, Inc.
Celgene Corporation
Hemostemix Ltd
ID Pharma Co., Ltd.
Juventas Therapeutics, Inc.
miRagen Therapeutics, Inc.
Multi Gene Vascular Systems Ltd
Nuo Therapeutics, Inc.
Proteon Therapeutics, Inc.
Recardio GmbH
Resverlogix Corp.
Sigma-Tau S.p.A.
Stemedica Cell Technologies, Inc.
Symic Biomedical, Inc.
Theravasc, Inc.
ViroMed Co., Ltd.
Yuyu Pharma, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Overview 10
Therapeutics Development 11
Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview 11
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Development by Companies 12
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Development by Companies 18
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies Involved in Therapeutics Development 20
Alvogen Korea Co., Ltd. 20
AnGes MG, Inc. 21
AstraZeneca Plc 22
Athersys, Inc. 23
Bayer AG 24
Betagenon AB 25
CardioVascular BioTherapeutics, Inc. 26
Celgene Corporation 27
Hemostemix Ltd 28
ID Pharma Co., Ltd. 29
Juventas Therapeutics, Inc. 30
miRagen Therapeutics, Inc. 31
Multi Gene Vascular Systems Ltd 32
Nuo Therapeutics, Inc. 33
Proteon Therapeutics, Inc. 34
Recardio GmbH 35
Resverlogix Corp. 36
Sigma-Tau S.p.A. 37
Stemedica Cell Technologies, Inc. 38
Symic Biomedical, Inc. 39
Theravasc, Inc. 40
ViroMed Co., Ltd. 41
Yuyu Pharma, Inc. 42
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Target 44
Assessment by Mechanism of Action 46
Assessment by Route of Administration 48
Assessment by Molecule Type 50
Drug Profiles 52
ACP-01 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
AEM-28 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ALD-301 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Annexin A-5 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
apabetalone - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
beperminogene perplasmid - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
CVBT-141C - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
DVC-10101 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
ELS-140 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
JVS-100 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
levocarnitine propionate hydrochloride - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
MGN-6114 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
MultiGeneAngio - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
O-304 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
PDA-002 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
PF-05285401 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
REC-03 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Rejuveinix - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
rivaroxaban - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
sarpogrelate SR - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
SB-030 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
sodium nitrite SR - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
ticagrelor - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
TXA-127 - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
V-10 - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
VM-202 - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
vonapanitase - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
YY-984 - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Recent Pipeline Updates 113
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects 165
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products 169
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Product Development Milestones 170
Featured News & Press Releases 170
Apr 13, 2016: Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease 170
Feb 04, 2016: Juventas Therapeutics Enrolls First Patient in Phase 2 Gene Therapy Clinical Trial for Treatment of Advanced Peripheral Artery Disease 170
Oct 12, 2015: Proteon Therapeutics Announces Results from Phase 1 Study of Investigational Drug Vonapanitase in Patients with Symptomatic Peripheral Artery Disease Presented at TCT 2015 171
Aug 13, 2015: Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease 172
Feb 02, 2015: The Small molecule AMPK activator O304 acts as an oral PCSK9 inhibitor 173
Jan 08, 2015: Journal of Cardiovascular Pharmacology Publishes Positive Nonclinical Results of Proteon Therapeutics' PRT-201 in Peripheral Artery Disease 173
Sep 02, 2014: Capstone Therapeutics Announces Phase 1a Results for AEM-28 Showing Safety and Biomarker Efficacy Signals 174
Mar 17, 2014: AstraZeneca Announces Progress on Global PARTHENON Clinical Trial Program with BRILINTA in High-Risk Cardiovascular Disease Patient Populations in Advance of American College of Cardiology Scientific Session 175
Mar 05, 2013: Tarix Pharma's Peptide Technology Stimulates Revascularization Following Ischemia 177
Dec 06, 2012: Cytomedix Announces Landmark Bright Cell Therapy Study In Peripheral Arterial Disease 177
Appendix 179
Methodology 179
Coverage 179
Secondary Research 179
Primary Research 179
Expert Panel Validation 179
Contact Us 179
Disclaimer 180
List of Tables
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Number of Products under Development by Companies, H1 2016 (Contd..1) 13
Comparative Analysis by Late Stage Development, H1 2016 14
Comparative Analysis by Clinical Stage Development, H1 2016 15
Comparative Analysis by Early Stage Development, H1 2016 16
Comparative Analysis by Unknown Stage Development, H1 2016 17
Products under Development by Companies, H1 2016 18
Products under Development by Companies, H1 2016 (Contd..1) 19
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Alvogen Korea Co., Ltd., H1 2016 20
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by AnGes MG, Inc., H1 2016 21
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by AstraZeneca Plc, H1 2016 22
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Athersys, Inc., H1 2016 23
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Bayer AG, H1 2016 24
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Betagenon AB, H1 2016 25
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by CardioVascular BioTherapeutics, Inc., H1 2016 26
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Celgene Corporation, H1 2016 27
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Hemostemix Ltd, H1 2016 28
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ID Pharma Co., Ltd., H1 2016 29
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Juventas Therapeutics, Inc., H1 2016 30
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by miRagen Therapeutics, Inc., H1 2016 31
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Multi Gene Vascular Systems Ltd, H1 2016 32
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Nuo Therapeutics, Inc., H1 2016 33
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Proteon Therapeutics, Inc., H1 2016 34
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Recardio GmbH, H1 2016 35
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Resverlogix Corp., H1 2016 36
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Sigma-Tau S.p.A., H1 2016 37
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Stemedica Cell Technologies, Inc., H1 2016 38
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Symic Biomedical, Inc., H1 2016 39
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Theravasc, Inc., H1 2016 40
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ViroMed Co., Ltd., H1 2016 41
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Yuyu Pharma, Inc., H1 2016 42
Assessment by Monotherapy Products, H1 2016 43
Number of Products by Stage and Target, H1 2016 45
Number of Products by Stage and Mechanism of Action, H1 2016 47
Number of Products by Stage and Route of Administration, H1 2016 49
Number of Products by Stage and Molecule Type, H1 2016 51
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Therapeutics - Recent Pipeline Updates, H1 2016 113
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, H1 2016 165
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects (Contd..1), H1 2016 166
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects (Contd..2), H1 2016 167
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects (Contd..3), H1 2016 168
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products, H1 2016 169
List of Figures
Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 15
Assessment by Monotherapy Products, H1 2016 43
Number of Products by Top 10 Targets, H1 2016 44
Number of Products by Stage and Top 10 Targets, H1 2016 44
Number of Products by Top 10 Mechanism of Actions, H1 2016 46
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 46
Number of Products by Routes of Administration, H1 2016 48
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 48
Number of Products by Molecule Types, H1 2016 50
Number of Products by Stage and Molecule Types, H1 2016 50
